康缘药业(600557) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was approximately ¥849.74 million, a decrease of 9.88% compared to the same period last year[2]. - The net profit attributable to shareholders for the same period was approximately ¥91.72 million, an increase of 24.28% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥64.47 million, reflecting a year-on-year increase of 17.56%[2]. - The basic earnings per share for Q3 2024 was ¥0.16, up 23.08% compared to the previous year[3]. - Total operating revenue for the first three quarters of 2024 was CNY 3,109,535,857.51, a decrease of 11.08% compared to CNY 3,496,031,021.85 in the same period of 2023[20]. - Net profit for the first three quarters of 2024 was CNY 363,983,299.76, representing a slight increase of 1.61% from CNY 359,753,803.62 in 2023[21]. - Basic earnings per share for the first three quarters of 2024 was CNY 0.62, up from CNY 0.61 in the same period last year[21]. - Total profit for the first three quarters of 2024 was CNY 427,258,722.90, a decrease of 1.79% from CNY 435,042,909.35 in 2023[21]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥6.90 billion, a decrease of 3.01% from the end of the previous year[3]. - As of September 30, 2024, total current assets decreased to ¥3,730,071,208.27 from ¥4,049,719,426.38 as of December 31, 2023, representing a decline of approximately 7.85%[18]. - Total assets decreased to ¥6,902,739,551.64 from ¥7,117,321,667.52, reflecting a decline of about 3.02%[19]. - Total liabilities decreased to ¥1,566,995,961.40 from ¥1,736,768,927.64, a reduction of approximately 9.76%[19]. - The company's equity attributable to shareholders decreased to ¥5,150,151,026.08 from ¥5,192,797,030.75, a decline of about 0.82%[19]. Cash Flow - The company's cash flow from operating activities was approximately ¥607.52 million, down 21.48% year-on-year[3]. - Cash flow from operating activities generated a net amount of CNY 607,522,057.90, down from CNY 773,730,389.33 in the previous year[22]. - Cash received from the sale of goods and services was CNY 3,603,590,620.18, a decrease of 14.31% compared to CNY 4,206,978,087.18 in 2023[22]. - Cash and cash equivalents decreased to ¥1,816,857,563.46 from ¥1,969,272,883.32, a reduction of about 7.75%[18]. - The net increase in cash and cash equivalents was CNY -155,388,878.10, compared to CNY -107,133,643.66 in the same period last year[23]. - Cash outflow from financing activities totaled CNY 429,395,392.37, significantly higher than CNY 130,969,189.44 in the previous year[23]. - Cash inflow from financing activities was not detailed, but the company reported a net cash flow from financing activities of CNY -429,395,392.37[23]. Investments and Expenditures - The company reported a significant increase in inventory by 55.99%, attributed to early stockpiling[5]. - The company’s investment income increased by 55.32%, primarily due to higher returns from financial investments[7]. - The company made investments totaling CNY 1,610,000,000.00, compared to CNY 957,000,000.00 in the previous period[23]. - The cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was CNY 309,921,739.98, an increase from CNY 239,777,125.32[23]. - The company reported a significant increase in development expenditures to ¥181,500,752.87 from ¥171,701,113.32, an increase of approximately 5.00%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,301, with the largest shareholder holding 30.28% of the shares[8]. - The company reported a total of 12,338,346 shares in the repurchase special securities account as of September 30, 2024[10]. - As of October 30, 2024, the company has repurchased a total of 12,338,346 shares, accounting for 2.1207% of the total share capital, with a total expenditure of ¥185,909,622.90[17]. - The company’s total number of shares held by the top ten shareholders does not include shares lent through margin trading[10]. Regulatory and Corporate Actions - The company received government subsidies amounting to approximately ¥28.31 million during the reporting period, contributing to its financial performance[4]. - The company received the drug registration certificate for the "Wen Yang Jie Du Granules," classified as a unique traditional Chinese medicine product, during the reporting period[15]. - The company obtained the clinical trial approval notice for the KYS202004A injection, a dual-target Fc fusion protein for psoriasis, during the reporting period[16]. - The estimated total amount for the construction framework agreement related to the national key laboratory project is 163.1085 million RMB[14]. - The company appointed Mr. Pan Peng as the secretary of the board of directors on July 12, 2024, following the resignation of Mr. Wu Yun as deputy general manager[11]. - The company’s major shareholders include Jiangsu Kangyuan Group Co., Ltd. and Shanghai Yinye Investment Co., Ltd., which are related parties[10]. - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending activities[11]. - The company’s new product, KYS202004A injection, is independently developed and has complete intellectual property rights[16]. - The company’s full subsidiary signed a construction framework agreement to ensure the progress of the traditional Chinese medicine manufacturing project[13]. - The company did not apply new accounting standards for the current reporting period[23]. - The board of directors announced the financial results on October 30, 2024[23].